Duration of the survival benefit of zidovudine therapy in HIV infection

Archives of Internal Medicine

Volumn 156, Issue 10, 1996, Pages 1073-1077

  Moore, Richard D ^a   Keruly, Jeanne C ^a   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SURVIVAL;

ADULT; ANTIVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; ZIDOVUDINE;

EID: 0029887208     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.10.1073     Document Type: Article

References (29)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317:185-191.
2. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA. 1989;262:2405-2410.
3. Graham NMH, Zeger SL, Park LP, et al. The effects on survival of early treatment of human immunodeficiency virus infection. N Engl J Med. 1992;326:1037-1042.
4. Lundgren JD, Phillips AN, Pedersen C, et al. Comparison of long-term prognosis of patients with AIDS treated and not treated with zidovudine. JAMA. 1994;271:1088-1092.
5. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus. N Engl J Med. 1990;327:941-949.
6. Cooper DA, Gatell JM, Kron S, et al. Zidovudine in persons with asymptomatic HIV infection and CD4+ counts greater than 400 per cubic millimeter. N Engl J Med. 1993;329:297-303.
7. Fischl MA, Richman DD, Hansen N, et al. The safety and efficacy of zidovudine in the treatment of subjects with mildly symptomatic HIV infection: a double-blind, placebo-controlled trial. Ann Intern Med. 1990;112:727-737.
8. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV-infection and prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA. 1994;272:437-442.
9. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic HIV infection: results of the VA Cooperative Study. N Engl J Med. 1992;326:437-443.
10. Concorde Coordinating Committee. Concorde: MRC/ANRS randomized double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet. 1994;343:871-881.
11. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in drug therapy for HIV disease in an urban community. N Engl J Med. 1993;330:763-768.
12. Barriett J. Medical Management of HIV Infection. Glenview, III: Physicians & Scientists Publishing Co; 1994.
13. Kaplan El, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Cox DR. Regression models and life-tables. J R Stat Soc B. 1972;34:187-220.
15. Lee E. Statistical Methods for Survival Data Analysis. 2nd ed. New York, NY: John Wiley & Sons Inc; 1992.
16. Larder BA, Duaby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243:1731-1734.
17. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr. 1990;3:743-746.
18. Boucher CA, Tersmette M, Lange JM, et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet. 1990;336:585-590.
19. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med. 1995;122:401-408.
20. Land S, McGavin C, Lucas R, Birch C. Incidence of zidovudine-resistant human immunodeficiency virus in patients before, during, and after therapy. J Infect Dis. 1992;166:1139-1142.
21. Montaner JSG, Singer S, Schechter MT, et al. Clinical correlates of in vitro HIV-1 resistance to zidovudine: results of the multicentre Canadian AZT trial. AIDS. 1993;7:189-196.
22. + cell depletion and progression to AIDS. Ann Intern Med. 1993;118:581-688.
23. St Clair MH, Hartigan PM, Andrews JC, et al. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr. 1993;6:891-897.
24. Boucher CAB, Lange JMA, Miedema FF, et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS. 1992;6:1259-1264.
25. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovidine with didanosine in human immunodeficiency virus infection. N Engl J Med. 1992;327:581-587.
26. Dolin R, Amato DA, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch Intern Med. 1995;155:961-974
27. + cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
28. 3. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 18,1995; San Francisco, Calif.
29. Markowitz M, Saag M, Powderly WG. A preliminary study of ritonavir, an inhibitor of HIV-I protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-1539.